Latest Breaking News On - பல ஏறுதல் டோஸ் - Page 1 : vimarsana.com

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results May 10, 2021 16:05 ET | Source: Larimar Therapeutics Larimar Therapeutics Bala Cynwyd, UNITED STATES - Topline data from placebo-controlled Phase 1 program in Friedreich s ataxia patients to be announced tomorrow, May 11, 2021- Management to discuss during webcast and conference call at 8 a.m. ET - Cash and investments of $81.4 million as of March 31, 2021 BALA CYNWYD, Pa., May 10, 2021 (GLOBE NEWSWIRE) Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2021 operating and financial results. “Our Phase 1 program in Friedreich s ataxia (FA) made strong progress over the past few months and we will be announcing topline data from the program tomorrow,” said Carole Ben-Maimon, MD, President and Chief Execu

Carole ben maimonMichael celanoJoyce allaireExchange commissionCompany contactLarimar therapeutics incChief executive officerMultiple ascending doseமகிழ்ச்சி அல்லேர்பரிமாற்றம் தரகுநிறுவனம் தொடர்புலாரிமார் சிகிச்சை இன்க்தலைமை நிர்வாகி அதிகாரிபல ஏறுதல் டோஸ்